CVRx Q2 FY26 net loss narrows 4.76% to $14 million; revenue rises 16% to $15.7 million

Reuters2026/08/06 21:12

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

CVRx posted Q2 2026 revenue of $15.7 million, up 16% year over year; net loss narrowed to $14 million, or $0.53 a share.
Gross margin rose 3 percentage points to 87%; gross profit climbed 20% to $13.7 million.
U.S. revenue increased 21% to $14.8 million on 466 units; Europe revenue fell 31% to $0.9 million on 40 units.
Active U.S. implanting centers grew to 258; Humana issued a Medicare Advantage coverage policy for Barostim effective May 1, 2026.
Forecast 2026 revenue of $58 million-$60 million; CEO Kevin Hykes cited fewer sales territories, lower productivity, and a prolonged issue with a major payer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CVRx Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-092005), on August 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

CVRx Q2 FY26 net loss narrows 4.76% to $14 million; revenue rises 16% to $15.7 million

You may also like

Crypto prices